✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
MLN1117 is an investigational drug.
There have been 8 clinical trials for MLN1117. The most recent clinical trial was a Phase 2 trial, which was initiated on June 30th 2016.
The most common disease conditions in clinical trials are Neoplasms, Carcinoma, Non-Small-Cell Lung, and Endometrial Neoplasms. The leading clinical trial sponsors are Millennium Pharmaceuticals, Inc., European Network of Individualized Treatment in Endometrial Cancer - ENITEC, and European Network of Translational Research in Ovarian Cancer - EUTROC.
There are seven US patents protecting this investigational drug and ninety-six international patents.
Recent Clinical Trials for MLN1117
|Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors||Avera McKennan Hospital & University Health Center||Phase 1|
|MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma||Millennium Pharmaceuticals, Inc.||Phase 2|
|A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer||European Network of Individualized Treatment in Endometrial Cancer - ENITEC||Phase 2|
Top disease conditions for MLN1117
Top clinical trial sponsors for MLN1117
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|MLN1117||See Plans and Pricing||Combination of PI3K-inhibitors||BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE)||See Plans and Pricing|
|MLN1117||See Plans and Pricing||Crystalline forms||Array Biopharma Inc. (Boulder, CO)||See Plans and Pricing|
|MLN1117||See Plans and Pricing||Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-- diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carb- onitrile||Loxo Oncology Inc. (Stamford, CT)||See Plans and Pricing|
|MLN1117||See Plans and Pricing||Heterocyclic compounds and uses thereof||INTELLIKINE, INC. (La Jolla, CA)||See Plans and Pricing|
|MLN1117||See Plans and Pricing||Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof||Intellikine LLC (La Jolla, CA)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|MLN1117||European Patent Office||EP3077003||2033-12-03||See Plans and Pricing|
|MLN1117||World Intellectual Property Organization (WIPO)||WO2015082378||2033-12-03||See Plans and Pricing|
|MLN1117||Argentina||AR113760||2037-10-10||See Plans and Pricing|
|MLN1117||Australia||AU2018348161||2037-10-10||See Plans and Pricing|
|MLN1117||Brazil||BR112020005463||2037-10-10||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|